Es gab 50 kürzliche Insider-Transaktionen für Quest Diagnostics Incorporated (DGX), darunter 11 Käufe und 33 Verkäufe. Die gesamten Insider-Käufe beliefen sich auf $27.15M und die gesamten Insider-Verkäufe auf $28.42M.
Bedeutende Insider mit kürzlicher Aktivität umfassen Wentworth Timothy C, Prevoznik Michael E, Plewman Patrick. Insider-Transaktionen können Einblicke geben, wie die Unternehmensführung die Bewertung und Zukunftsaussichten der Aktie einschätzt.
Insider-Transaktionen — DGX
| Datum |
Name |
Funktion |
Transaktionsart |
Aktien |
Ø Preis |
Wert |
Gehaltene Aktien |
| 2026-04-01 |
Wentworth Timothy C |
Director |
RSU-Zuteilung |
198 |
- |
- |
198 |
| 2026-03-09 |
Wentworth Timothy C |
Director |
Unbekannt |
- |
- |
- |
- |
| 2026-03-09 |
Wentworth Timothy C |
Director |
RSU-Zuteilung |
215 |
- |
- |
215 |
| 2026-03-05 |
Prevoznik Michael E |
SVP & General Counsel |
Informierter Verkauf |
3,878 |
$206.21 |
$799.68K |
37,557 |
| 2026-03-05 |
Plewman Patrick |
SVP For Diagnostic Services |
Informierter Verkauf |
2,855 |
$206.21 |
$588.73K |
15,198 |
| 2026-03-05 |
Doherty Catherine T. |
EVP, Regional Businesses |
Informierter Verkauf |
5,558 |
$206.21 |
$1.15M |
67,122 |
| 2026-03-04 |
Prevoznik Michael E |
SVP & General Counsel |
RSU-Steuereinbehalt |
3,354 |
$204.86 |
$687.1K |
41,435 |
| 2026-03-04 |
Plewman Patrick |
SVP For Diagnostic Services |
RSU-Steuereinbehalt |
2,827 |
$204.86 |
$579.14K |
18,053 |
| 2026-03-04 |
Doherty Catherine T. |
EVP, Regional Businesses |
RSU-Steuereinbehalt |
5,806 |
$204.86 |
$1.19M |
72,680 |
| 2026-03-04 |
Davis J. E. |
CEO and President |
RSU-Steuereinbehalt |
26,414 |
$204.86 |
$5.41M |
142,423 |
| 2026-03-04 |
Samad Sam |
Executive Vice President & CFO |
RSU-Steuereinbehalt |
7,720 |
$204.86 |
$1.58M |
33,268 |
| 2026-03-04 |
Deppe Michael J |
SVP, Corp. Controller & CAO |
RSU-Steuereinbehalt |
750 |
$204.86 |
$153.65K |
35,196 |
| 2026-03-04 |
Kuppusamy Karthik |
SVP, Clinical Solutions |
Informierter Verkauf |
2,628 |
$204.86 |
$538.37K |
13,441 |
| 2026-03-04 |
Delaney Mark E |
SVP & Chief Commercial Officer |
RSU-Steuereinbehalt |
2,326 |
$204.86 |
$476.5K |
11,864 |
| 2026-03-03 |
Prevoznik Michael E |
SVP & General Counsel |
Informierter Verkauf |
526 |
$207.73 |
$109.27K |
37,557 |
| 2026-03-03 |
Plewman Patrick |
SVP For Diagnostic Services |
Informierter Verkauf |
410 |
$207.73 |
$85.17K |
15,198 |
| 2026-03-03 |
Doherty Catherine T. |
EVP, Regional Businesses |
Informierter Verkauf |
632 |
$207.73 |
$131.29K |
67,122 |
| 2026-03-02 |
Prevoznik Michael E |
SVP & General Counsel |
RSU-Steuereinbehalt |
288 |
$204.86 |
$59K |
38,083 |
| 2026-03-02 |
Plewman Patrick |
SVP For Diagnostic Services |
RSU-Steuereinbehalt |
230 |
$204.86 |
$47.12K |
15,608 |
| 2026-03-02 |
Doherty Catherine T. |
EVP, Regional Businesses |
RSU-Steuereinbehalt |
648 |
$204.86 |
$132.75K |
67,754 |
| 2026-03-02 |
Davis J. E. |
CEO and President |
Informierter Verkauf |
10,000 |
$212.52 |
$2.13M |
117,185 |
| 2026-03-02 |
Samad Sam |
Executive Vice President & CFO |
RSU-Steuereinbehalt |
869 |
$204.86 |
$178.02K |
27,041 |
| 2026-03-02 |
Deppe Michael J |
SVP, Corp. Controller & CAO |
RSU-Steuereinbehalt |
88 |
$204.86 |
$18.03K |
34,473 |
| 2026-03-02 |
Kuppusamy Karthik |
SVP, Clinical Solutions |
RSU-Steuereinbehalt |
205 |
$204.86 |
$42K |
9,869 |
| 2026-03-02 |
Delaney Mark E |
SVP & Chief Commercial Officer |
RSU-Steuereinbehalt |
188 |
$204.86 |
$38.51K |
8,508 |
| 2026-02-19 |
Prevoznik Michael E |
SVP & General Counsel |
Informierter Verkauf |
1,111 |
$204.83 |
$227.57K |
38,371 |
| 2026-02-19 |
Plewman Patrick |
SVP For Diagnostic Services |
Informierter Verkauf |
958 |
$204.83 |
$196.23K |
15,838 |
| 2026-02-19 |
Doherty Catherine T. |
EVP, Regional Businesses |
Informierter Verkauf |
1,433 |
$204.83 |
$293.52K |
68,402 |
| 2026-02-18 |
Prevoznik Michael E |
SVP & General Counsel |
RSU-Zuteilung |
9,289 |
$204.96 |
$1.9M |
9,289 |
| 2026-02-18 |
Plewman Patrick |
SVP For Diagnostic Services |
RSU-Zuteilung |
9,009 |
$204.96 |
$1.85M |
9,009 |
| 2026-02-18 |
Doherty Catherine T. |
EVP, Regional Businesses |
RSU-Zuteilung |
13,514 |
$204.96 |
$2.77M |
13,514 |
| 2026-02-18 |
Davis J. E. |
CEO and President |
RSU-Zuteilung |
73,225 |
$204.96 |
$15.01M |
73,225 |
| 2026-02-18 |
Samad Sam |
Executive Vice President & CFO |
RSU-Zuteilung |
18,303 |
$204.96 |
$3.75M |
18,303 |
| 2026-02-18 |
Deppe Michael J |
SVP, Corp. Controller & CAO |
RSU-Zuteilung |
1,688 |
$204.96 |
$345.97K |
1,688 |
| 2026-02-18 |
Kuppusamy Karthik |
SVP, Clinical Solutions |
RSU-Steuereinbehalt |
259 |
$206.99 |
$53.61K |
7,914 |
| 2026-02-18 |
Delaney Mark E |
SVP & Chief Commercial Officer |
RSU-Zuteilung |
7,332 |
$204.96 |
$1.5M |
7,332 |
| 2026-02-13 |
Doherty Catherine T. |
EVP, Regional Businesses |
Optionsausübung (Verkauf) |
26,165 |
$112.17 |
$2.93M |
- |
| 2026-02-10 |
Plewman Patrick |
SVP For Diagnostic Services |
Optionsausübung (Verkauf) |
5,662 |
$121.81 |
$689.66K |
- |
| 2026-01-28 |
Plewman Patrick |
SVP For Diagnostic Services |
RSU-Zuteilung |
48 |
$183.51 |
$8.81K |
15,381 |
| 2026-01-28 |
Carter Robert B |
Director |
Kleintransaktion |
6 |
$183.51 |
$1.1K |
2,704 |
| 2026-01-28 |
Gregg Vicky B |
Director |
Kleintransaktion |
67 |
$183.51 |
$12.3K |
17,104 |
| 2026-01-28 |
Samad Sam |
Executive Vice President & CFO |
RSU-Zuteilung |
69 |
$183.51 |
$12.66K |
27,910 |
| 2026-01-28 |
Lassiter Wright Iii |
Director |
Kleintransaktion |
7 |
$183.51 |
$1.28K |
9,057 |
| 2026-01-28 |
Kuppusamy Karthik |
SVP, Clinical Solutions |
Kleintransaktion |
16 |
$183.52 |
$2.94K |
10,065 |
| 2026-01-28 |
Delaney Mark E |
SVP & Chief Commercial Officer |
Kleintransaktion |
15 |
$183.51 |
$2.75K |
8,696 |
| 2025-11-25 |
Gregg Vicky B |
Director |
Informierter Verkauf |
1,250 |
$191.76 |
$239.7K |
17,037 |
| 2025-11-25 |
Davis J. E. |
CEO and President |
Optionsausübung (Verkauf) |
55,093 |
$95.80 |
$5.28M |
- |
| 2025-11-18 |
Delaney Mark E |
SVP & Chief Commercial Officer |
Optionsausübung (Verkauf) |
7,846 |
$144.47 |
$1.13M |
- |
| 2025-11-05 |
Davis J. E. |
CEO and President |
RSU-Steuereinbehalt |
7,143 |
$175.57 |
$1.25M |
120,480 |
| 2025-10-23 |
Pfeiffer Gary M |
Director |
Ermessensverkauf |
4,413 |
- |
- |
- |
■ Informativ — Transaktion am offenen Markt (bedeutendste)
■ Nicht-informativ (Kauf) — Vergütung, Optionsausübung, Wandlung
■ Nicht-informativ (Verkauf) — Quellensteuer, Verkauf bei Vesting
■ Neutral — Schenkung, Treuhand, Verfall
